Study Finds TREMFYA® Reduces Fatigue in PsA Patients
Moderate to severe fatigue affects nearly 50% of psoriatic arthritis (PsA) patients and greatly impacts their quality of life. Dr. Alyssa Johnsen, MD, PhD, Vice President, Rheumatology Disease Area Lead, Janssen Research & Development discusses a new publication in “Arthritis Research & Therapy” that supports TREMFYA’s (guselkumab) ability to reduce fatigue in psoriatic arthritis (PsA) patients. The two phase 3 clinical trials of 1,120 patients with active PsA found that guselkumab 100 mg every four weeks or every eight weeks led to clinical and sustained improvements in fatigue through one year.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Arthritis. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Arthritis and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Arthritis?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Moderate to severe fatigue affects nearly 50% of psoriatic arthritis (PsA) patients and greatly impacts their quality of life. Dr.
- Key Point: Alyssa Johnsen, MD, PhD, Vice President, Rheumatology Disease Area Lead, Janssen Research & Development discusses a new publication in “Arthritis Research & Therapy” tha…
- Key Point: The two phase 3 clinical trials of 1,120 patients with active PsA found that guselkumab 100 mg every four weeks or every eight weeks led to clinical and sustained improvement…
- Key Point: Alyssa Johnsen, M.D., Ph.D., is Vice President, Rheumatology and Maternal-Fetal Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Deve…
- Key Point: In this role, Alyssa is responsible for driving scientific leadership in rheumatology and maternal-fetal health, overseeing innovative compounds across multiple phases of develo…
Alyssa Johnsen, M.D., Ph.D., is Vice President, Rheumatology and Maternal-Fetal Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Alyssa is responsible for driving scientific leadership in rheumatology and maternal-fetal health, overseeing innovative compounds across multiple phases of development.
Prior to her role at Janssen, Alyssa held clinical development, translational and portfolio leadership roles across Immunology and Oncology at Bristol-Myers Squibb, encompassing both early and late development. She led development of a portfolio of immune-oncology assets from Phase 1 through POC, as well as early registrational trials. Within Immunology, she held a variety of roles including leader of the translational team for a key marketed asset and the leader of the late-phase clinical development group.
Earlier in her career, Alyssa was a faculty member in the Division of Rheumatology at the Brigham and Women’s Hospital and subsequently the University of Pennsylvania, performing basic and translational research in autoimmune diseases as well as caring for rheumatology patients.
Alyssa received her bachelor’s degree in chemistry at Duke University and her Ph.D. in immunology and M.D. at Case Western Reserve University. She completed residency training in internal medicine at the Massachusetts General Hospital and a fellowship in Rheumatology at the Brigham and Women’s Hospital.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.


